Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome

Tseng, Ling-Hong; Wang, Alex C.; Chang, Yao‐Lung; Soong, Yung‐Kuei; Lloyd, L. Keith; Ko, Y.H.

doi:10.1002/nau.20583

Cited by 74 publications

(46 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A controlled study of 229 femmes presenting an overactive detrusor did not show any benefit for topical vaginal oestrogen therapy associated with tolterodine versus tolterodine alone for overactive bladder symptoms (LE2) [29]. Another randomised controlled trial in 80 women with overactive bladder syndrome, also comparing the effect of topical vaginal oestrogen therapy associated with tolterodine with that of tolterodine alone, found a significant improvement of objective parameters and quality of life when oestrogens were associated with tolterodine (LE2) [30]. Finally, a recent randomised trial comparing the efficiency of topical vaginal oestrogen therapy with that of oxybutynin for the treatment of overactive bladder syndrome found that the two products were similar in terms of efficiency (LE2) [31].…”

Section: Data Obtained From Random Studies Of Women Treated For Urinamentioning

confidence: 99%

Menopause, hormone treatment and urinary incontinence at midlife

et al. 2013

View full text Add to dashboard Cite

Section: Data Obtained From Random Studies Of Women Treated For Urinamentioning

confidence: 99%

Menopause, hormone treatment and urinary incontinence at midlife

et al. 2013

View full text Add to dashboard Cite

“…[30], прово-дивших лечение 80 пациенток с ГМП, показана достовер-ная предпочтительность применения комбинации толте-родина и вагинальных форм эстрогенов по сравнению с использованием только толтеродина.…”

Section: треугольник льето 40unclassified

Specific features of therapy for disordered urination in menopausal women

Балан¹,

Amirova²,

Kovaleva³

et al. 2015

Ross. vestn. akush.-ginekol.

View full text Add to dashboard Cite

Пероральные формы препаратов для заместительной гормональной терапии негативно воздействуют на тече-ние стрессового недержания мочи и увеличивают риск его развития de novo. Вагинальные формы эстрогенов оказы-вают терапевтический эффект на все симптомы гиперак-тивного мочевого пузыря (ГМП), включая ургентное не-держание мочи.Менопауза -универсальный физиологический про-цесс, связанный с падением секреции овариальных гор-монов (эстрогены, прогестерон). Диагноз «менопауза» правомочен в отсутствие менструации в течение 12 мес у женщин в возрасте 47-51 года [1]. Время наступления ме-нопаузы зависит от многих факторов, таких как социаль-ный статус женщины, характер питания, образ жизни (ку-рение) и масса тела. Помимо климактерического синдро-ма, характеризующегося вазомоторными нарушениями, падение уровня половых стероидов служит причиной воз-никновения урогенитальных расстройств, включающих различные виды недержания мочи.Урогенитальные расстройства -комплекс вагиналь-ных и мочевых симптомов, связанных с развитием атро-фических и дистрофических процессов в эстрогензависи-мых тканях и структурах нижней трети мочеполового В статье представлен обзор литературы, отражающий современные возможности лечения женщин с гиперактивным моче-вым пузырем в зависимости от возраста. Показана чувствительность нижних отделов урогенитального тракта к половым стероидам, значимость которых в генезе симптомов гиперактивного мочевого пузыря не вызывает сомнений. Рассмо-трены вопросы проведения различных видов заместительной гормональной терапии в состав комплексной терапии.Авторы информируют об отсутствии конфликта интересов. Ключевые слова: гиперактивный мочевой пузырь, менопауза, урогенитальные расстройства, эстрогены, антимускариновые препаратыThe paper gives a literature review reflecting the current possibilities of treatment in women with overactive bladder depending upon age. It shows the susceptibility of the lower urogenital tract to sex steroids, the significance of which in the genesis of overactive bladder is beyond question. Different hormone replacement therapy options as part of combination therapy are considered. The authors declare no conflicts of interest.

show abstract

“…One study evaluating the combination of tolterodine and conjugated equine estrogen cream reported that the combination was associated with significant improvements in daytime frequency and voided volume (but not nocturia, urgency or urgency incontinence) compared to tolterodine alone. 15 The investigators of another study, which evaluated tolterodine with or without oestriol cream, reported that there was no difference between arms in any of the efficacy endpoints. 16 Subjects all had detrusor overactivity rather than just symptoms of OAB.…”

Section: Estrogensmentioning

confidence: 99%

Systematic review of overactive bladder therapy in females

Cardozo

2013

CUAJ

View full text Add to dashboard Cite

Although the prevalence of overactive bladder (OAB) is similar in both male and female populations, females have a greater tendency to seek medical advice regarding their symptoms. A review of the evidence of therapy among women shows that a variety of modalities has been shown to be effective for symptom improvement in women with OAB. Bladder retraining/re-education should be considered for all women with OAB. With respect to first-line pharmacotherapy with antimuscarinic agents, the development of extended release preparations, bladder selective M3 antagonists and alternative routes of delivery, have improved compliance and persistence. Other pharmacotherapeutic options with potential for providing benefit include antidepressants, vasopressin analogues, alpha-adrenoceptor antagonists and beta-adrenoceptor agonists. There are also a number of newer agents currently being investigated, including calcium channel blocking agents, potassium channel opening drugs, beta agonists and neurokinin receptor antagonists. Intravesical injections of botulinum toxin may be an alternative, while surgery can be considered for truly intractable cases.

show abstract

Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome

Abstract: A combination of vaginal estrogen cream and tolterodine is a potential therapy for postmenopausal women with OAB.

Cited by 74 publications

References 29 publications

Menopause, hormone treatment and urinary incontinence at midlife

Menopause, hormone treatment and urinary incontinence at midlife

Specific features of therapy for disordered urination in menopausal women

Systematic review of overactive bladder therapy in females

Contact Info

Product

Resources

About